Advancements in Real-World Data for Rare Disease Research

This technical report discusses the transformative role of real-world data (RWD) in advancing research for rare diseases, particularly in North America. It outlines how RWD is being utilized to overcome the challenges associated with conducting clinical trials in small, dispersed patient populations. The report details various initiatives and collaborations among patient advocacy groups, researchers, and regulatory bodies that are enhancing the understanding of rare diseases and improving trial design. It highlights the significance of electronic health records (EHRs) and emerging technologies, such as wearable sensors and advanced analytics, in facilitating data collection and patient recruitment. The report also addresses the evolving regulatory frameworks that support the use of RWD in research. Additionally, it presents a case study of the FDA's approval of Skyclarys, the first treatment for Friedreich’s Ataxia, showcasing the impact of RWD on drug development. The report concludes with a forward-looking perspective on the integration of artificial intelligence in rare disease research methodologies.